Replies to post #147579 on Biotech Values

[jq1234]

While the cause of these unexpected events, which involve heart and kidney toxicity

Both heart and kidney toxicity!!!

I suppose FDA put IDX184 on partial clinical hold only when they got more information from BMY, not just 1 severe cardio event as originally reported.

[DewDiligence]

BMY will have to take a world-class write-off in the current quarter. On a GAAP basis, it will wipe out most of BMY’s profit for the year.

[DewDiligence]

Today, BMY also dumped the other drug acquired from INHX—FV-100 for shingles:

http://finance.yahoo.com/news/synergy-pharmaceuticals-acquires-fv-100-204500451.html

This looks like a fire sale to have a clean break with everything related to INHX. It may simplify the accounting for the coming charge against GAAP earnings.

[BTH]

I wonder if INHX shareholders think they still got screwed?